Early changes in eDiary COPD symptoms predict trough FEV1 and TDI responders at 12 weeks in the CRYSTAL trial Source: International Congress 2017 – Management of COPD Year: 2017
NVA237 once daily provides rapid, clinically meaningful and sustained 24-h bronchodilation in patients with COPD: The GLOW1 trial Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011
Salmeterol provides sustained health status improvement over 12 months in patients with COPD Source: Eur Respir J 2002; 20: Suppl. 38, 241s Year: 2002
Spirometric changes in bronchodilation tests as predictors of asthma diagnosis and treatment response in patients with FEV1 =80% predicted Source: Virtual Congress 2021 – Advances in asthma treatment Year: 2021
Does an acute FEV1 response predict long-term improvements with bronchodilators in patients with COPD? Source: Eur Respir J 2001; 18: Suppl. 33, 486s Year: 2001
Clinically meaningful improvements with reslizumab in patient-reported outcomes and lung function in a sub-population defined by the EU indication with =3 exacerbations Source: International Congress 2017 – Asthma: mechanisms and treatment Year: 2017
Clinical indicators of treatment response to Mepolizumab at 12 weeks Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020
Immediate bronchodilation response in FEV1 as a diagnostic criterion of adult asthma Source: International Congress 2018 – Clinical markers of asthma Year: 2018
Maintenance of bronchodilation following tiotropium in patients with mild, moderate and severe COPD in one year clinical trials Source: Eur Respir J 2001; 18: Suppl. 33, 331s Year: 2001
An increase in steps per day 6 weeks after pulmonary rehabilitation of COPD patients correlates with an improvement in quality of life Source: Virtual Congress 2020 – Optimising the benefits of pulmonary rehabilitation Year: 2020
Follow-up of patients with severe asthma receiving reslizumab: an FEV1 analysis Source: International Congress 2017 – Asthma management Year: 2017
IsovolumeFEF25-75% 6 and FEV1 for identifying bronchodilator response Source: Eur Respir J 2006; 28: Suppl. 50, 156s Year: 2006
Are 6MWD and FEV1 the most clinically relevant measures? Source: Annual Congress 2012 - Life's a gas: aspects of respiratory gas exchange Year: 2012
Follow-up results 10 years after early intervention with budesonide or terbutaline in mild persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 667s Year: 2006
The effect of single dose inhaled budesonide on Amppc20 in patients with mild asthma: a 3 month follow up Source: Eur Respir J 2005; 26: Suppl. 49, 369s Year: 2005
A clinically significant bronchodilator response in children: how should it be measured? Source: Eur Respir J, 55 (5) 2000636; 10.1183/13993003.00636-2020 Year: 2020
The different results of the six minutes walking-test in COPD patients with or without significant improvement of inspiratory capacity after bronchodilator test Source: Eur Respir J 2004; 24: Suppl. 48, 122s Year: 2004
Volume response are more significant and important than flow response to bronchodilator in patients with COPD Source: Annual Congress 2009 - Accuracy in lung function testing Year: 2009
Significant percentage of asthma patients failed to achieve control in the first year after initiating medium or high dose ICS/LABA Source: International Congress 2017 – Primary care management of asthma and self-management of respiratory disease Year: 2017
Effect of once-daily tadalafil on exercise capacity and clinical deterioration with up to 68 weeks of treatment in patients with PAH Source: Annual Congress 2009 - Pulmonary arterial hypertension Year: 2009